CurrentCapital BluecrossPolicy AHS - G2158

Testing for Vector-Borne Infections

Defines medical necessity coverage criteria and exclusions for laboratory testing methods (culture, NAAT, serology, microscopy, IFA, PCR, PRNT, antigen/NS1, RDT) for a range of vector-borne infections (babesiosis, relapsing fever/Borrelia spp., chikungunya, Colorado tick fever, dengue, Zika, ehrlichiosis/anaplasmosis, malaria, rickettsial diseases, West Nile virus, yellow fever) and related testing limitations.

Policy Summary

PayerCapital Bluecross

PolicyTesting for Vector-Borne Infections

Policy CodePolicy AHS - G2158

Change TypeRevision date updated

Effective DateSep 25, 2018

Next Review DateN/A

Key ActionConfirm the individual's benefit coverage and applicable Medicare/Medicaid rules prior to ordering testing as coverage is dependent on individual benefits.

SourceLink

POLICY UPDATE CHANGES

Policy revision date updated to 03/01/2026 as shown in header.

19Specific numbered coverage statements present

MultipleVector-borne pathogens addressed

~40Procedure codes listed

CDC/IDSA/ASMAuthoritative guidance referenced

Pathogens covered (examples)

Coverage Summary

Policy AHS - G2158: Coverage criteria for diagnostic laboratory testing of vector-borne infections (culture, microscopy/stains, NAAT/PCR, serology/IFA/ELISA, antigen/NS1, RDT, PRNT, LDTs) and related limitations. Coverage stance: mixed (tests and modalities may meet or not meet coverage depending on pathogen, clinical scenario, specimen type, and timing). Effective date: 2018-09-25. Last review / policy revision: 2026-03-01. Policy number: AHS - G2158.

Key thresholds

Serologic confirmatory timingInitial and confirmatory serologic testing should occur a minimum of two weeks apart

Malaria microscopy repeatSmear microscopy can be repeated up to three times within three days if initial microscopy is negative

Zika NAAT window - pregnant symptomaticNAAT meets coverage up to 12 weeks after symptom onset for symptomatic pregnant individuals with relevant travel/exposure

Zika NAAT window - symptomatic non-pregnant (travel-associated)NAAT meets coverage when symptoms presented within 7 days for symptomatic non-pregnant individuals in areas with active CDC Zika Travel Health Notice

Babesiosis serology confirmationConfirmatory serology requires a four-fold change in IgG titer between paired sera (e.g., 1:64 to 1:256)

Medical Necessity Criteria (by pathogen)

Coverage depends on individual benefit coverage. The following diagnostic test recommendations by pathogen describe which tests MEET or DO NOT MEET coverage criteria.

ALL of the following

Babesiosis: For individuals suspected of having babesiosis, the use of a Giemsa- or Wright-stain of a blood smear, nucleic acid amplification testing (NAAT), or IgG or IgM indirect immunofluorescence antibody (IFA) assay for Babesia meets coverage criteria; initial testing and confirmatory testing should occur a minimum of two weeks apart.
Serologic timing: initial and confirmatory testing separated by >= 2 weeks.

ALL of the following

- Depending on suspected type
  - HTRF (hard tick relapsing fever): serologic assays to detect Borrelia antibodies or NAAT testing to detect Borrelia miyamotoi.

Testing Recommendations & Evidence Summary

Testing recommendations summarized from CDC/IDSA/ASM guidelines

Guideline-based recommended diagnostic tests and specimen types for specific vector-borne infections:

This policy provides clinical background on arthropod-borne bacterial, protozoan, and viral pathogens (eg, rickettsial diseases, ehrlichiosis/anaplasmosis, Lyme and other Borrelia spp., babesiosis, malaria, dengue, Zika, West Nile, chikungunya, yellow fever, Colorado tick fever) and summarizes diagnostic approaches including culture, microscopy and stain techniques (Giemsa/Wright, dark-field), nucleic acid amplification tests (NAAT/PCR/RT‑PCR), antigen detection (NS1, RDTs), serologic assays (IFA, ELISA, MAC‑ELISA), and confirmatory plaque reduction neutralization testing (PRNT). Epidemiologic trends from CDC and WHO note a substantial rise in reported vector-borne diseases in the U.S. (more than 640,000 cases reported 2004–2016), changing patterns by vector (tickborne diseases increasing steadily; mosquito-borne diseases showing epidemic behavior), and ongoing public‑health surveillance and guidance from CDC/WHO for specific pathogens and specimen windows.

Evidence highlights and guidance

CDC surveillance 2004-2016More than 640,000 vector-borne disease cases reported in US/territories (2004-2016)

RMSF cases 2023

Applicable Codes

Applicable CPT/HCPCS procedure codes (listed in policy)CPT

86280	Hemagglutination inhibition test (HAI)
86382	Neutralization test, viral
86619	Antibody; Borrelia (relapsing fever)
86666	Antibody; Ehrlichia
86750	Antibody; Plasmodium (malaria)
86753	Antibody; protozoa, not elsewhere specified
86757	Antibody; Rickettsia
86788	Antibody; West Nile virus, IgM
86789	Antibody; West Nile virus
86790	Antibody; virus, not elsewhere specified

1–10 of 25

1/3

Applicable CPT/HCPCS procedure codesmixed

No codes listed

No specific billing/coding provided in this partmixed

No codes listed

Note: the proprietary U-codes 0043U and 0044U correspond to IGeneX tick‑borne relapsing fever (TBRF) IgM/IgG immunoblot assays listed in the policy's CPT/HCPCS table. Providers must report the specific CPT/HCPCS code that corresponds to the organism/test performed as listed in the policy when submitting claims and follow applicable billing guidance.

Provider Actions & Billing Implications

Documentation Required

Serologic timing documentation

Document serologic timing in the medical record: initial and convalescent serologic tests should be performed at least two weeks apart for rickettsial diseases and babesiosis; paired serology is required to support tickborne rickettsial diagnoses. Clearly note symptom onset date, exposure history, and indications for repeat testing when suspicion persists.

Documentation Required

Malaria repeat testing

For suspected malaria, if initial smear microscopy is negative but clinical suspicion remains, repeat smear microscopy up to three times within three days is indicated. To confirm Plasmodium species, order NAAT. Repeat NAAT may be appropriate to rule out false-positive results when clinical and laboratory findings are discordant.

Repeat microscopy: up to 3 times within 3 days when initial smear is negative but suspicion persists
Confirm species: NAAT to confirm Plasmodium species

Definitions & Specimen/Timing Guidance

Key definitions used in the policy include: NAAT — nucleic acid amplification testing (eg, PCR, RT‑PCR) for pathogen DNA/RNA; IFA — indirect immunofluorescence antibody assay for detection of IgG/IgM antibodies; PRNT — plaque reduction neutralization test used as a confirmatory serologic assay for flaviviruses; RDT — rapid diagnostic test (immunochromatographic antigen or antibody assays); and LDT — laboratory‑developed test (performed and validated in‑house under CLIA as high complexity). These terms convey the primary testing modalities, their purposes, and regulatory/validation considerations.

Specimen selection and timing recommendations: collect optimum specimen types and time sampling relative to symptom onset per pathogen. For babesiosis, use whole blood (EDTA preferred) for smears and NAAT, and obtain paired sera for IFA with acute and convalescent samples to demonstrate a fourfold rise (acute within 2 weeks of onset; convalescent 2–10 weeks after). For relapsing fevers and babesiosis/HTRF/STRF, whole blood is preferred for NAAT and microscopy (dark‑field or Giemsa/Wright) during febrile episodes. For malaria, perform STAT Giemsa‑stained thick and thin smears (repeat every 12–24 hours up to 3 exams before ruling out) and consider RDTs as an alternative when microscopy is not immediately available; use PCR/NAAT for species confirmation. For neuroborreliosis and other CNS presentations, collect paired CSF and serum (ideally within 24 hours) for antibody testing or CSF/serum index evaluation. For Zika and other arboviruses, follow specific windows: Zika NAAT on serum/urine/whole blood/CSF for pregnant symptomatic individuals up to 12 weeks after symptom onset or travel, and Zika/DENV NAAT on serum collected ≤ 7 days after symptom onset for symptomatic non‑pregnant individuals; perform PRNT to resolve cross‑reactive flavivirus IgM positives. Collect infant specimens as soon as possible after birth (serum, urine, CSF when obtained) for congenital Zika evaluation.

Revision History

2018-09-25effective_date

Policy effective date published as 09/25/2018.

2026-03-01last_reviewLatest

Document last reviewed; policy revision date updated to 03/01/2026 (header).

Policy Summary

PayerCapital Bluecross

PolicyTesting for Vector-Borne Infections

Policy CodePolicy AHS - G2158

Change TypeRevision date updated

Effective DateSep 25, 2018

Next Review DateN/A

Key ActionConfirm the individual's benefit coverage and applicable Medicare/Medicaid rules prior to ordering testing as coverage is dependent on individual benefits.

SourceLink

On This Page

LBRF (louse-borne relapsing fever): peripheral blood smear microscopy or NAAT testing to detect Borrelia recurrentis.

STRF/TBRF (soft tick or tickborne relapsing fever): dark-field microscopy of a peripheral blood smear, microscopy of a Wright- or Giemsa-stained blood smear, NAAT testing to detect Borrelia spp., or serologic assays to detect Borrelia antibodies.

Culture testing for Borrelia does NOT meet coverage criteria.

ALL of the following

Chikungunya: For individuals suspected of having chikungunya, the use of viral culture for diagnosis, NAAT for detection of chikungunya in blood, or IFA assay for IgM antibodies during both the acute and convalescent phases meets coverage criteria.

ALL of the following

Colorado tick fever (CTF): For individuals suspected of having CTF, the use of NAAT testing or IFA for CTF-specific IgM antibodies meets coverage criteria.

ALL of the following

Dengue virus (DENV): For detection of DENV, the use of NAAT, IgM antibody capture ELISA (MAC-ELISA), or NS1 ELISA, as well as a confirmatory plaque reduction neutralization test (PRNT) for DENV, meets coverage criteria for individuals suspected of having DENV and for individuals who are symptomatic for Zika virus infection when DENV testing is indicated by clinical scenario or travel history.
IgG ELISA or hemagglutination testing for DENV does NOT meet coverage criteria.

ALL of the following

Zika virus (ZIKV): NAAT meets coverage criteria in: symptomatic pregnant individuals up to 12 weeks after symptom onset who lived in or traveled to areas with current or past Zika transmission or had sexual exposure to such areas; symptomatic non-pregnant individuals living in or with recent travel to areas with active CDC Zika Travel Health Notice when symptoms presented within the last 7 days.
Zika NAAT and IgM testing plus confirmatory PRNT meet coverage criteria in: symptomatic pregnant individuals up to 12 weeks after symptom onset in areas with active CDC Zika Travel Health Notice; pregnant individuals with a fetus with prenatal ultrasound findings consistent with congenital Zika; infants born to individuals who tested positive during pregnancy; infants with signs of congenital Zika syndrome with possible prenatal exposure; symptomatic non-pregnant individuals in areas with active CDC Zika Travel Health Notice when symptoms presented >7 days prior to testing.
Zika NAAT and/or IgM testing does NOT meet coverage criteria for non-pregnant individuals who have not traveled outside the United States and its territories and are symptomatic.

ALL of the following

Ehrlichiosis and Anaplasmosis: For individuals suspected of ehrlichiosis and/or anaplasmosis, NAAT of whole blood, IFA assay for IgG antibodies, or microscopy for morulae detection meets coverage criteria.
IFA assay for IgM antibodies or standard blood culture does NOT meet coverage criteria.

ALL of the following

Malaria: For individuals suspected of malaria, the use of a rapid immunochromatographic diagnostic test (RDT) or smear microscopy to diagnose malaria, determine Plasmodium species, identify life-cycle stage, and/or quantify parasitemia meets coverage criteria. Smear microscopy can be repeated up to three times within three days if initial microscopy is negative in suspected cases.
NAAT testing meets coverage criteria to confirm the species of Plasmodium in an individual diagnosed with malaria (confirmatory role).
IFA for Plasmodium antibodies does NOT meet coverage criteria.

ALL of the following

Rickettsial diseases: For individuals suspected of a rickettsial disease, IFA assay for IgG antibodies meets coverage criteria; initial and confirmatory testing should occur a minimum of two weeks apart.
Standard blood culture, NAAT, or IFA assay for IgM antibodies do NOT meet coverage criteria for rickettsial diseases.

ALL of the following

West Nile virus (WNV): For individuals suspected of WNV disease, IFA for WNV-specific IgG or IgM antibodies in serum or CSF and a confirmatory PRNT meet coverage criteria.
Nucleic acid detection (NAAT) of WNV meets coverage criteria to confirm infection in immunocompromised individuals.
NAAT for WNV does NOT meet coverage criteria for immunocompetent individuals suspected of WNV disease.

ALL of the following

Yellow fever virus (YFV): For individuals suspected of YFV infection, NAAT for YFV or serologic assays to detect virus-specific IgM and IgG antibodies, plus a confirmatory PRNT for YFV, meet coverage criteria.

ALL of the following

Asymptomatic/general exam testing: For asymptomatic individuals during a general exam without abnormal findings, testing for babesiosis, chikungunya virus, CTF, DENV, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, TBRF, WNV, YFV, or Zika virus DOES NOT MEET COVERAGE CRITERIA.

1,205 Rocky Mountain spotted fever cases reported to CDC in 2023

MC004 assay performanceReported zero false positives/negatives; within- and between-run precision <20% CV at tested parasitemia levels

BinaxNOW malaria performanceFDA-approved RDT; reported sensitivity ~84.2% with misclassification and potential false-positives

Babesiosis qPCR evidenceqPCR sensitivity 96.2% and specificity 70.5% vs FISH/microscopy (Akoolo et al. 2017)

Zika RDT (Kim 2018)IgG sens/spec 99.0%/99.3%; IgM 96.7%/98.7%; cross-reactivity with dengue 16.7% (IgG) and 5.6% (IgM)

Key guideline referencesIDSA/ASM 2024, WHO 2022 interim guidance, AAP Red Book 2021-2024, multiple CDC references

Repeat NAAT: consider to rule out false-positives when results conflict with clinical picture

Denial Risk

Asymptomatic screening denial risk

Asymptomatic screening for vector-borne infections during a general exam without abnormal findings is a denial risk. Do not order routine screening tests for babesiosis, chikungunya, Colorado tick fever, dengue, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, tickborne relapsing fever, West Nile, yellow fever, or Zika in asymptomatic individuals without exposure or clinical signs.

Asymptomatic screening denial risk: testing without symptoms or exposure may be denied
Tests commonly affected include: babesiosis, chikungunya, CTF, DENV, ehrlichiosis/anaplasmosis, malaria, rickettsial disease, TBRF, WNV, YFV, Zika

Documentation Required

Paired serology required for tickborne rickettsial diagnosis

For tickborne rickettsial disease, paired serology (acute and convalescent samples at least 2 weeks apart) is required for accurate diagnosis; single IgM or IgG results without paired testing are insufficient and may not meet coverage criteria.

Paired serology required: acute and convalescent samples >= 2 weeks apart
Single serology without pairing: may be non-diagnostic and denied

Documentation Required

Confirmatory testing for flaviviruses

Confirmatory testing is required for flavivirus infections (e.g., dengue, West Nile, Zika, yellow fever). Positive IgM or ELISA results should be confirmed with plaque reduction neutralization testing (PRNT) when indicated; for immunocompromised patients consider nucleic acid detection where specified by policy.

Confirmatory PRNT for flaviviruses (DENV, WNV, Zika, YFV) when initial serology positive
Immunocompromised: consider nucleic acid detection (NAAT) per policy

Documentation Required

Repeat NAAT to rule out false-positives

Repeat NAAT may be needed to rule out false-positive molecular results when initial NAAT is inconsistent with clinical presentation or other laboratory findings. Document rationale for repeat molecular testing in the record.

Repeat NAAT: consider when NAAT positive but clinical picture or serology do not support infection
Document indication for repeat molecular testing in the chart

Note

Refer to public health labs/CDC when indicated

Refer specimens to public health laboratories or CDC when indicated (e.g., for confirmatory PRNT, rare pathogens, epidemiologic surveillance, or when local lab testing is insufficient). Coordinate specimen submission and reporting per local public health guidance.

Refer to public health labs/CDC for PRNT or specialized testing
Follow local public health submission and reporting procedures

Prior Authorization

Repeat testing when suspicion persists

When clinical suspicion persists despite negative initial testing, repeat testing (NAAT or serology as appropriate) and documentation of ongoing concern is recommended. Ensure benefit verification/prior authorization per member benefits before ordering tests that may require prior approval.

Repeat testing when suspicion persists: order repeat NAAT or convalescent serology as clinically indicated
Prior authorization: verify benefits/obtain prior auth when required

Billing Rule

Billing rule: test codes to verify

Billing/Coding note: ensure correct coding and documentation for molecular and serologic tests. Codes to reference when ordering/billing include: 87468, 87469, 87478, 87484, 87662, 0043U, 0044U, 87798, 87899. Confirm coverage and prior authorization requirements with payer before submission.

Affected codes: 87468, 87469, 87478, 87484, 87662, 0043U, 0044U, 87798, 87899
Verify coverage and prior authorization requirements with payer